About arrowhead pharmaceuticals inc. - ARWR
Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.
ARWR At a Glance
Arrowhead Pharmaceuticals, Inc.
177 East Colorado Boulevard
Pasadena, California 91105
| Phone | 1-626-304-3400 | Revenue | 829.45M | |
| Industry | Biotechnology | Net Income | -1,631,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 23,258.153% | |
| Fiscal Year-end | 09 / 2026 | Employees | 711 | |
| View SEC Filings |
ARWR Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 5.562 |
| Price to Book Ratio | 10.043 |
| Price to Cash Flow Ratio | 25.69 |
| Enterprise Value to EBITDA | 36.516 |
| Enterprise Value to Sales | 5.383 |
| Total Debt to Enterprise Value | 0.164 |
ARWR Efficiency
| Revenue/Employee | 1,166,593.53 |
| Income Per Employee | -2,293.952 |
| Receivables Turnover | 121.549 |
| Total Asset Turnover | 0.64 |
ARWR Liquidity
| Current Ratio | 4.863 |
| Quick Ratio | 4.863 |
| Cash Ratio | 4.703 |
ARWR Profitability
| Gross Margin | 97.115 |
| Operating Margin | 11.857 |
| Pretax Margin | 6.213 |
| Net Margin | -0.197 |
| Return on Assets | -0.126 |
| Return on Equity | -0.501 |
| Return on Total Capital | -0.136 |
| Return on Invested Capital | -0.149 |
ARWR Capital Structure
| Total Debt to Total Equity | 157.425 |
| Total Debt to Total Capital | 61.154 |
| Total Debt to Total Assets | 50.583 |
| Long-Term Debt to Equity | 147.278 |
| Long-Term Debt to Total Capital | 57.212 |